Stock-Based Compensation (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Share-Based Payment Arrangement [Abstract]

Schedule of stock option activity

13. Stock-Based Compensation

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		—
Granted		6,632,387			3.68
Exercised		—			—
Cancelled/forfeited		(469,181	)		5.32
Outstanding as of September 30, 2022		6,163,206		$	3.56		9.55	$	—

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		31,962,921		$	2.81		7.77	$	86,075
Granted		—
Exercised		(1,606,795	)		2.52				3,658
Cancelled/forfeited		(5,083,652	)		2.57
Outstanding as of September 30, 2022		25,272,474		$	2.82		7.17	$	74

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		9,526,727		$	5.55		8.0	$	13,905
Granted		—			—
Exercised		(2,181,335	)		2.5				1,678
Cancelled/forfeited		(888,381	)		8.04
Outstanding as of September 30, 2022		6,457,011		$	6.51		7.99	$	—

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		30,402,801		$	2.45		8.75	$	885
Granted		5,287,031			4.74
Exercised		(2,757,671	)		2.30				7,740
Expired/forfeited		(969,240	)		3.65
Outstanding as of December 31, 2021		31,962,921		$	2.81		7.77	$	86,075
Exercisable as of December 31, 2021		14,777,334		$	2.51		6.93	$	41,622
Vested and expected to vest as of December 31, 2021		26,660,149		$	2.73		7.59	$	72,705

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		6,490,208		$	2.49		9.26	$	1,174
Granted		5,516,399			7.82
Exercised		(1,630,925	)		2.54				8,807
Expired/Forfeited		(848,955	)		2.68
Outstanding as of December 31, 2021		9,526,727		$	5.55		8.01	$	13,905
Exercisable as of December 31, 2021		3,637,954		$	2.95		6.24	$	9,364
Vested and expected to vest as of December 31, 2021		7,608,158		$	4.81		7.68	$	13,896

Schedule of weighted-average assumptions

	September 30, 2022			September 30, 2021
Risk-free interest rate:		2.46	%		0.79	%
Expected term (in years):		7.16			6.05
Expected volatility:		42.17	%		42.10	%
Dividend yield:		0.00	%		0.00	%

	2021			2020
Risk-free interest rate:		0.79	%		0.45	%
Expected term (in years):		6.05			6.13
Expected volatility:		42.10	%		37.25	%
Dividend yield:		0.00	%		0.00	%

	2021			2020
Risk-free interest rate:		1.39	%		0.59	%
Expected term (in years):		9.06			10
Expected volatility:		35.86	%		38.42	%
Dividend yield:		0.00	%		0.00	%

Schedule of stock-based compensation expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Research and development	$	2,311	$	1,879	$	7,012	$	2,873
Sales and marketing		301		538		926		847
General and administrative		707		2,636		1,855		4,801
	$	3,319	$	5,053	$	9,793	$	8,521

	2021		2020
Research and development	$	4,001	$	941
Sales and marketing		1,185		387
General and administrative		6,159		8,177
	$	11,345	$	9,505

Restricted stock awards for employee bonus, net	2021		2020
Research and development	$	7,613	$	—
Sales and marketing		2,310		—
General and administrative		8,694		—
	$	18,617	$	—